Kinoxis Therapeutics
PrivateLast Round
Grant
Dec 23, 2024
Total Funding Raised
$22.37M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Kinoxis Therapeutics is a biotechnology company developing novel small-molecule therapies for the treatment of neuropsychiatric disorders, including substance use disorders, agitation, and aggression.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Mental Health
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Kinoxis Therapeutics Comparables
Compare Kinoxis Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Astraea Therapeutics | 80% | |
| Occentis | 80% | |
| Proniras Corporation | 76% |
Kinoxis Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Dec 23, 2024 | ||||
| Series B | Aug 12, 2024 | ||||
| Grant | Jun 8, 2023 | ||||
| VC Round | Dec 22, 2020 | ||||
| Grant | Sep 29, 2019 | ||||
Series A | Feb 15, 2018 |
Key People
Founding team and executive leadership
Kinoxis Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Institute on Drug Abuse | Grant |
| CUREator | Grant |
| NIH RADx | Grant |
| UniSuper Management | Series B |
| Avicella Capital | Series B |
| National Institutes of Health (NIH) | Grant |
| Uniseed | VC Round, Series B, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 26, 2026
Monthly visitors increased 58% MoM.
- May 16, 2026
Monthly visitors grew 107% MoM, reaching 505.
Recent news
Latest coverage and updates
- receives_financingSep 23, 2026
Kinoxis Therapeutics Pty Ltd receives financing of $6.75M in equity funding.
- is_developingSep 23, 2026
Kinoxis Therapeutics Pty Ltd is developing treatment for chronic agitation and aggression associated with dementia.
Kinoxis Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Kinoxis Therapeutics's valuation, stock price, and market status.
Is Kinoxis Therapeutics a public or private company?
Kinoxis Therapeutics is a private company.
What is the current stock price of Kinoxis Therapeutics?
Kinoxis Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Kinoxis Therapeutics worth (valuation)?
Valuation information for Kinoxis Therapeutics is not publicly available.
Can I buy Kinoxis Therapeutics stock?
Kinoxis Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Kinoxis Therapeutics's last funding round?
Kinoxis Therapeutics's most recent funding round was Grant on December 23, 2024.
Who are the main investors in Kinoxis Therapeutics?
Key investors in Kinoxis Therapeutics include Uniseed.
Will Kinoxis Therapeutics IPO soon?
No public IPO plans have been announced for Kinoxis Therapeutics.
How can I track Kinoxis Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Kinoxis Therapeutics's secondary market activity and sign up for updates.